Wilson Sonsini advised LinusBio on the deal. Linus Biotechnology received $16 million in venture capital financing for its R&D efforts to establish a method for predicting...
LinusBio’s $16 Million Financing to Help Diagnose Autism
Metagenomi’s $100 Million Series B Extension Financing
Wilson Sonsini Goodrich & Rosati advised Novo Holdings and Metagenomi on the deal. Fenwick represented Metagenomi. Gene editing company Metagenomi announced a $100 million Series B...
Escient Pharmaceuticals’ $120 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised NEA and Abingworth on the transaction. Escient Pharmaceuticals announced that it had raised $120 million through a Series C Financing...
Rezo Therapeutics’ $78 Million Series A Financing
Wilson Sonsini represented lead investors SR One and Norwest in the transaction. Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision...
Inversago Pharma’s $70 Million Series C Financing
White & Case and Osler, Hoskin & Harcourt LLP advised Inversago Pharma Inc. on the deal, while Wilson Sonsini advised NEA. Inversago Pharma Inc., a clinical-stage...
BIOMILQ, Inc.’s $21 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the deal. North Carolina-based mammary biotechnology company BIOMILQ, Inc., announced the successful close of $21 million in...
ARS Pharmaceuticals’ $55 Million Series D Financing
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better...
Codex DNA’s $122 Million IPO
Wilson Sonsini Goodrich & Rosati advised Codex DNA on the deal. Codex DNA, Inc. (Nasdaq: DNAY) announced the closing of its initial public offering of 7,666,664...
Aerpio Pharmaceuticals’ Merger with Aadi Bioscience
Wilson Sonsini Goodrich & Rosati advised Aadi Bioscience on the deal while Goodwin Procter LLP represented Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals and Aadi Bioscience announced their...
Vividion Therapeutics’ $135 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics, Inc. and the lead investors on the deal. Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies...
Arya Sciences Acquisition Corp III’s Merger with Nautilus Biotechnology
Wilson Sonsini Goodrich & Rosati, P.C. advised Nautilus Biotechnology, while Kirkland & Ellis LLP, working alongside Ogier, advised Arya III on the deal. Latham & Watkins...